Analyst consensus rating
Senti Biosciences Holdings Analyst Rating: none
SNTI is rated none by 2 analysts with a $13.50 target. As of 2026-09-01.
Direct answer
Senti Biosciences Holdings's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.50.
Forecast evidence checked September 1, 2026.
Get free Senti Biosciences Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.38
- Average price target
- $13.50
- High price target
- $15.00
- Low price target
- $12.00
- Low target gap
- +3,072.1%
- Target upside
- +3,468.6%
- High target gap
- +3,865.1%
- Target range width
- 793%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Senti Biosciences Holdings?
Senti Biosciences Holdings has a verified none consensus. The same dataset has an average price target of $13.50.
How far are Senti Biosciences Holdings's low and high targets from the recorded price?
The low target implies +3,072.1%, while the high target implies +3,865.1%.
How many analysts are included in Senti Biosciences Holdings's consensus?
The verified consensus includes 2 analysts.
How is Senti Biosciences Holdings's target upside or downside calculated?
The average target of $13.50 is divided by the recorded price of $0.38, then one is subtracted to produce +3,468.6%. This does not guarantee a future return.
When was Senti Biosciences Holdings's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.